Related Experiment Video
Updated: Jun 5, 2025

12:03
Fertility Preservation in Patients with Severe Ovarian Dysfunction
Published on: March 25, 2021
4.5K
Evidence-based guideline: premature ovarian insufficiency†‡
, Nick Panay1, Richard A Anderson2
1Queen Charlotte's and Chelsea Hospital, Imperial College London, London, UK.
Climacteric : the Journal of the International Menopause Society
|December 8, 2024
Summary
This guideline offers updated recommendations for diagnosing and managing premature/primary ovarian insufficiency (POI), emphasizing current evidence for women's health and fertility. It addresses diagnosis, sequelae, and treatments, including hormone therapy (HT).
Area of Science:
- Reproductive Endocrinology
- Women's Health
- Clinical Guidelines
Background:
- Premature/primary ovarian insufficiency (POI) significantly impacts women's physical and emotional health, affecting quality of life, fertility, and long-term health (bone, cardiovascular, cognitive).
- Optimal management of POI remains a challenge, despite hormone therapy (HT) offering some mitigation of adverse effects.
Purpose of the Study:
- To provide evidence-based recommendations for the diagnosis and management of premature/primary ovarian insufficiency (POI).
- To update clinical practice guidelines for healthcare professionals caring for women with POI, incorporating new evidence and expanded clinical questions.
Main Methods:
- Development of the guideline followed the European Society of Human Reproduction and Embryology (ESHRE) methodology, including expert consensus and literature review up to January 2024.
- Key questions were informed by a survey of women and healthcare professionals; recommendations were formulated and refined through consensus, with input from women with lived experience of POI.
Main Results:
- The updated guideline addresses 40 clinical questions on POI diagnosis, sequelae (bone, cardiovascular, neurological, sexual function, fertility, well-being), and treatments, including HT.
- Key changes include requiring only one elevated follicle stimulating hormone (FSH) >25 IU/L for POI diagnosis, guidance on anti-Müllerian hormone (AMH) testing, and updated recommendations on genetic testing, estrogen/contraceptive use, and testosterone therapy.
- New topics include fertility preservation, muscle health, iatrogenic POI management, and expanded complementary/non-hormonal treatments and lifestyle management.
Conclusions:
- This guideline provides clear, evidence-based advice for best practice in POI care, aiming to improve outcomes for affected women.
- It highlights areas where evidence is limited and provides research recommendations to guide future studies in POI management.
Related Concept Videos
Oogenesis
63.4K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
63.4K
Infertility in Females
275
Female infertility is defined as the inability to conceive after a year of regular, unprotected intercourse and affects about 10–15% of couples worldwide. The primary cause of female infertility is ovulatory disorders, which hinder the release of eggs. These disorders can be classified as hypothalamic amenorrhea, polycystic ovarian syndrome (PCOS), premature ovarian failure, and hyperprolactinemic anovulation disorders.
Endometriosis, a condition characterized by abnormal growth of...
Endometriosis, a condition characterized by abnormal growth of...
275

